by Elec23 | Dec 5, 2025 | News&events
A new scientific paper authored by Emanuele Montomoli and Claudia Maria Trombetta has just been published in Expert Review of Vaccines: “High-dose influenza vaccine: enhanced protection for the elderly.” The review highlights the added value of the high-dose influenza...
by Elec23 | Dec 3, 2025 | News&events
VisMederi is pleased to announce the establishment of VisMederi America, a new company based in Cleveland that marks a strategic milestone in the Group’s expansion into the United States. The new entity aims to strengthen VisMederi’s international presence,...
by Elec23 | Nov 27, 2025 | News&events
VisMederi is once again included in the “Leader of Growth 2026” ranking compiled by Il Sole 24 Ore in collaboration with Statista, where it ranks among the Italian companies that have performed the best in terms of revenue growth and development over the...
by Elec23 | Nov 3, 2025 | News&events
A new milestone in bacterial vaccine research: after several years of intensive research, validation work, and cross-institutional collaboration, the study on the development and qualification of a Multiplex assay for Shigella has now been officially published on...
by Elec23 | Oct 23, 2025 | News&events
We are proud to be part of Clover Biopharmaceuticals’ important achievement in advancing innovative respiratory combination vaccines. VisMederi contributed to the RSV+hMPV±PIV3 Combination Vaccines Phase I study by performing serological analyses, supporting the...
by Elec23 | Oct 22, 2025 | News&events
VisMederi continues to strengthen its engagement in metapneumovirus control and vaccine research, confirming its active role in the international scientific community. At the 10th ESWI Influenza Conference, held in Valencia from 20 to 23 October 2025, Maria Giovanna...
